Pharmacological activation of TFEB by SFN, a previously identified TFEB agonist (Li et al., 2021), significantly promoted cholesterol clearance in human and mouse NPC cells, while genetic inhibition (KO) of TFEB blocked SFN-induced cholesterol clearance. This evidence concerns the gene SFN and nasopharyngeal carcinoma.